MYLUNG Consortium Part 3: Observational Study

Recruiting now

Conditions studied: Carcinoma, Non-Small-Cell Lung

In brief

This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.

Key facts

Study ID

NCT05885698

Run by

US Oncology Research

People needed

7500

Starts

2023-01-30

Expected to finish

2030-12-01

Last updated by the study team

2026-05-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult subjects (18 years and older) with newly diagnosed early stage, locally advanced or metastatic non-small cell lung cancer
• Must be eligible for systemic therapy based on the treating provider's assessment. If systemic therapy was recommended and documented by the treating provider but the patient declined, they can still be eligible for the study. Patients can be enrolled prior to start of treatment.
• Subjects who developed locally advanced or metastatic disease after receiving adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of locally advanced or metastatic disease
• Subjects must be enrolled within 30 days of initiation of systemic therapy
• Signed informed consent

You may not qualify if…

• Stage IA at the time of enrollment
• Subjects with small cell lung cancer
• Subjects with Unknown primary tumor origin

Where it is running

• Southern Cancer Center, PC — Daphne, Alabama, United States (enrolling)
• Cancer Care Centers of Brevard, Inc. — Palm Bay, Florida, United States (enrolling)
• Affiliated Oncologists, LLC — Chicago Ridge, Illinois, United States (enrolling)
• New York Oncology Hematology, P.C. — Albany, New York, United States (enrolling)
• Oncology Hematology Care Clinical Trials, LLC — Cincinnati, Ohio, United States (enrolling)
• Willamette Valley Cancer Institute and Research Center — Eugene, Oregon, United States (enrolling)
• Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Blacksburg, Virginia, United States (enrolling)
• Virginia Oncology Associates — Newport News, Virginia, United States (enrolling)
• Northwest Cancer Specialists, P.C. — Vancouver, Washington, United States (enrolling)
• Arizona Oncology Associates, PC - NAHOA — Prescott Valley, Arizona, United States
• Rocky Mountain Cancer Center — Denver, Colorado, United States
• Virginia Cancer Specialists, PC — Fairfax, Virginia, United States
• Woodlands Medical Specialists, PA — Pensacola, Florida, United States
• Shenandoah Oncology, P.C. — Winchester, Virginia, United States
• Illinois Cancer Specialists — Niles, Illinois, United States
• Maryland Oncology Hematology, P.A. — Silver Spring, Maryland, United States
• Minnesota Oncology Hematology, P.A. — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.